Your Weekly Dose of News in Pharma, Biotech and Health
The biotech sector faces a crisis in gene therapy, with leading experts seeking solutions. The FDA's accelerated approval process is likely to focus on more rare disease drugs. Early-stage biopharma funding is expected to drop 40% this year, while pharma deals aim for innovation and first-in-class drugs. New molecular entities (NMEs) have seen significant progress this year. In the marketing realm, pharmaceutical companies are employing various strategies, including social media campaigns and key opinion leader (KOL) talks to boost drug uptake. On the policy and regulation front, the EU has approved data sharing with the US, and labiotech.eu highlights the upcoming deadline for the EU HTA regulation.
BiotechGene therapy is in crisis. For nine hours, the field’s leading minds looked for a solution
The future of accelerated approval for FDA's Marks? More rare disease drugs and no 'hanging chads'
Early-Stage Biopharma Funding to Drop 40% This Year: Report
Pharma deals seek novelty with heavy focus on first-in-class
Banner year for NMEs so far
MarketingRx roundup: Sanofi teases #DefeatMeningitis on social; Moderna launches mRNAMonday series on Threads
Tatiana Prowell, Vincent Rajkumar are biggest oncology influencers on X, the platform formerly known as Twitter
Pre-launch KOL talks linked to 1.5-time boost to drug uptake
Policy & Regulation
EU approves data sharing with the US
What you need to know about the EU HTA regulation before deadline